ELICIO THERAPEUTICS INC (ELTX) Fundamental Analysis & Valuation

NASDAQ:ELTX • US28657F1030

Current stock price

13.55 USD
+0.95 (+7.54%)
At close:
13.55 USD
0 (0%)
After Hours:

This ELTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ELTX Profitability Analysis

1.1 Basic Checks

  • In the past year ELTX has reported negative net income.
  • In the past year ELTX has reported a negative cash flow from operations.
  • ELTX had negative earnings in each of the past 5 years.
  • ELTX had a negative operating cash flow in each of the past 5 years.
ELTX Yearly Net Income VS EBIT VS OCF VS FCFELTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -153.01%, ELTX is doing worse than 84.11% of the companies in the same industry.
  • ELTX's Return On Equity of -2418.77% is on the low side compared to the rest of the industry. ELTX is outperformed by 83.33% of its industry peers.
Industry RankSector Rank
ROA -153.01%
ROE -2418.77%
ROIC N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELTX Yearly ROA, ROE, ROICELTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • ELTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELTX Yearly Profit, Operating, Gross MarginsELTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ELTX Health Analysis

2.1 Basic Checks

  • ELTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ELTX has been increased compared to 5 years ago.
  • The debt/assets ratio for ELTX has been reduced compared to a year ago.
ELTX Yearly Shares OutstandingELTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
ELTX Yearly Total Debt VS Total AssetsELTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -10.77, we must say that ELTX is in the distress zone and has some risk of bankruptcy.
  • ELTX has a Altman-Z score of -10.77. This is in the lower half of the industry: ELTX underperforms 74.81% of its industry peers.
  • ELTX has a Debt/Equity ratio of 5.75. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 5.75, ELTX is doing worse than 81.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.75
Debt/FCF N/A
Altman-Z -10.77
ROIC/WACCN/A
WACCN/A
ELTX Yearly LT Debt VS Equity VS FCFELTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 2.38 indicates that ELTX has no problem at all paying its short term obligations.
  • ELTX's Current ratio of 2.38 is on the low side compared to the rest of the industry. ELTX is outperformed by 73.84% of its industry peers.
  • ELTX has a Quick Ratio of 2.38. This indicates that ELTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.38, ELTX is doing worse than 70.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
ELTX Yearly Current Assets VS Current LiabilitesELTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ELTX Growth Analysis

3.1 Past

  • ELTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.57%, which is quite impressive.
EPS 1Y (TTM)38.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ELTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.58% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y32.79%
EPS Next 2Y20.27%
EPS Next 3Y12.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELTX Yearly Revenue VS EstimatesELTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2029 2030 2031 2032 5M 10M 15M 20M 25M
ELTX Yearly EPS VS EstimatesELTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. ELTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ELTX. In the last year negative earnings were reported.
  • Also next year ELTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELTX Price Earnings VS Forward Price EarningsELTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELTX Per share dataELTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ELTX's earnings are expected to grow with 12.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.27%
EPS Next 3Y12.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ELTX Dividend Analysis

5.1 Amount

  • No dividends for ELTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELTX Fundamentals: All Metrics, Ratios and Statistics

ELICIO THERAPEUTICS INC

NASDAQ:ELTX (4/17/2026, 8:08:18 PM)

After market: 13.55 0 (0%)

13.55

+0.95 (+7.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners12.08%
Inst Owner Change0%
Ins Owners2.22%
Ins Owner Change35.77%
Market Cap249.32M
Revenue(TTM)N/A
Net Income(TTM)-39.57M
Analysts82.5
Price Target17.85 (31.73%)
Short Float %10.72%
Short Ratio9.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.05%
Min EPS beat(2)-6.95%
Max EPS beat(2)0.86%
EPS beat(4)2
Avg EPS beat(4)-0.83%
Min EPS beat(4)-6.95%
Max EPS beat(4)5.54%
EPS beat(8)3
Avg EPS beat(8)-9.13%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.9%
PT rev (3m)12.9%
EPS NQ rev (1m)-15.29%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 152.4
P/tB 152.4
EV/EBITDA N/A
EPS(TTM)-2.58
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -153.01%
ROE -2418.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 5.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -10.77
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.79%
Cap/Depr(5y)101.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.88%
EPS Next Y32.79%
EPS Next 2Y20.27%
EPS Next 3Y12.58%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.38%
OCF growth 3YN/A
OCF growth 5YN/A

ELICIO THERAPEUTICS INC / ELTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ELICIO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELTX.


Can you provide the valuation status for ELICIO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ELICIO THERAPEUTICS INC (ELTX). This can be considered as Overvalued.


What is the profitability of ELTX stock?

ELICIO THERAPEUTICS INC (ELTX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ELICIO THERAPEUTICS INC?

The Earnings per Share (EPS) of ELICIO THERAPEUTICS INC (ELTX) is expected to grow by 32.79% in the next year.